Zotiraciclib diHCl (TG-02, SB-1317)

Zotiraciclib diHCl (TG-02, SB-1317) Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.

Zotiraciclib diHCl (TG-02, SB-1317) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(3)Suppliers